NEWS OF THE W EEK
BRINGING HIV OUT OF HIDING DRUG DISCOVERY: Bryostatin analogs fight dormant HIV, may be key to HIV/AIDS cure
T
HE SYNTHESIS of analogs of a bryostatin natu-
ral product could advance the eradication of AIDS by ferreting HIV out of its hiding places in immune cells. Highly active antiretroviral therapy (HAART), the current standard for HIV drug treatment, fights the virus by attacking it in multiple ways simultaneously. But HAART drugs are toxic and attack only the active virus. People infected with HIV must take the drugs for life because of HIV’s latency—its tendency to adopt a dormant provirus form in immune cells, from which the virus emerges over time to reestablish active infection. If HIV latency could be eliminated, HAART could actually cure patients. Certain natural products can bring the provirus out of dormancy. Obtained from the bark of a Samoan tree, the natural product prostratin is being considered for clinical testing even though its potency in activating latent HIV is low. The natural product bryostatin 1 has similar activity and about 1,000 times the potency of prostratin. Coming from an aquatic invertebrate, it is difficult to obtain and hence expensive. Bryostatin 1 also causes side effects such as muscle pain. Now, Jerome A. Zack, codirector of the UCLA AIDS Institute; Paul A. Wender, a synthetic organic chemist at Stanford University; and coworkers report the synthesis of promising analogs. In vitro tests show that the
analogs, dubbed “bryologs, ” are at least as potent as bryostatin 1 in activating dormant HIV (Nat. Chem., DOI: 10.1038/nchem.1395). They are also readily accessible by synthesis, easily modifiable, and seemingly nontoxic. Studies of the bryologs in an animal model are in progress. The work is “a significant accomplishment, since prostratin is too impotent,” says Douglas D. Richman, director of the UC San Diego Center for AIDS Research. The bryologs are “a promising class of drugs for activating the latent HIV reservoir, but animal and clinical confirmation of the agents’ activity is still needed,” he says. “The new bryologs are an important discovery, and I am intrigued with their improved potency,” says Warner C. Greene, director of the Gladstone Institute of Virology & Immunology at UC San Francisco. “They could well become part of a cocktail of drugs. Of course, two important issues are whether they will synergize with other agents and have acceptable toxicity profiles.” “The tour de force complex synthesis of bryologs is a brilliant realization of the goals of function-oriented synthesis,” says synthetic chemist Erick M. Carreira of the Swiss Federal Institute of Technology, Zurich. “This strategy brings the viral terrorists out of hiding, where they can be targeted for destruction. The combination of the new bryologs with other current antiretroviral therapies is highly promising and offers new hope for treatment.”—STU
Bryostatin 1 (top) and seven analogs with similar anti-HIV activity synthesized by Wender and coworkers.
BORMAN
ENGINEERING POLYMERS Amid shortage, Evonik plans nylon 12 plant for Singapore Evonik Industries has picked Singapore as the location of a new plant for nylon 12, a specialty polymer used to make automotive brake and fuel lines. The company announced the decision as it attempts to recover from a plant explosion that has severely limited supplies of the polymer. The Singapore plant will have 20,000 metric tons of annual capacity and should be completed in 2014, Evonik says. The company currently makes nylon 12 in Marl, Germany. Nylon 12 supply was already tight on March 31 when an explosion occurred at an Evonik plant in Marl that makes
cyclododecatriene (CDT), a critical precursor for nylon 12. Two workers were killed in the explosion. The plant supplies both Evonik and Evonik’s main rival in nylon 12, Arkema. Weeks after the accident, automakers and their parts suppliers convened an emergency meeting near Detroit over a looming nylon 12 shortage (C&EN, April 23, page 6). There, Evonik and Arkema offered customers substitute nylons. That same month, the auto industry drafted guidelines for the fast-track approval of nylon 12 replacements in applications such as connectors and multilayer tubing. Evonik says the CDT plant should be
WWW.CEN-ONLIN E .ORG
11
J ULY 16, 20 1 2
repaired in the fourth quarter, enabling nylon 12 supplies to return to normal soon thereafter. With inventories of nylon 12 now waning, many consumers will have to resort to alternative materials this summer, says Paul Blanchard, North American director of engineering resins for the consulting group IHS Chemical. “System suppliers are engaged in submitting testing results to their customers to obtain fast-track approvals for substitute materials,” he says. The industry, he notes, was looking for nylon 12 alternatives even before the explosion because tight supply drove up prices.—ALEX TULLO
